X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (60) 60
index medicus (59) 59
female (55) 55
breast neoplasms - drug therapy (48) 48
oncology (41) 41
breast cancer (39) 39
breast neoplasms - pathology (31) 31
middle aged (25) 25
chemotherapy (23) 23
docetaxel (23) 23
aged (21) 21
adult (20) 20
paclitaxel (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
treatment outcome (18) 18
cancer (16) 16
tamoxifen (16) 16
chemotherapy, adjuvant (15) 15
disease-free survival (15) 15
trastuzumab (15) 15
anastrozole (14) 14
doxorubicin (13) 13
postmenopausal women (13) 13
neoplasm metastasis (12) 12
neoplasm staging (11) 11
therapy (11) 11
prognosis (10) 10
randomized controlled trials as topic (10) 10
survival (10) 10
taxoids - therapeutic use (9) 9
abridged index medicus (8) 8
aged, 80 and over (8) 8
cyclophosphamide (8) 8
doxorubicin - administration & dosage (8) 8
endocrine therapy (8) 8
letrozole (8) 8
metastasis (8) 8
nitriles - therapeutic use (8) 8
paclitaxel - administration & dosage (8) 8
taxoids (8) 8
triazoles - therapeutic use (8) 8
antibodies, monoclonal, humanized (7) 7
antineoplastic agents - adverse effects (7) 7
antineoplastic agents - therapeutic use (7) 7
antineoplastic agents, hormonal - therapeutic use (7) 7
antineoplastic agents, phytogenic - therapeutic use (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
aromatase inhibitor (7) 7
care and treatment (7) 7
disease progression (7) 7
postmenopause (7) 7
survival analysis (7) 7
adjuvant (6) 6
adjuvant treatment (6) 6
anthracyclines (6) 6
aromatase inhibitors (6) 6
breast neoplasms - metabolism (6) 6
breast neoplasms - mortality (6) 6
clinical-trials (6) 6
colony-stimulating factor (6) 6
drug therapy (6) 6
health aspects (6) 6
medicine & public health (6) 6
multicenter (6) 6
paclitaxel - analogs & derivatives (6) 6
pharmacology & pharmacy (6) 6
postmenopausal (6) 6
quality of life (6) 6
research (6) 6
taxoids - administration & dosage (6) 6
women (6) 6
animals (5) 5
antibodies, monoclonal - administration & dosage (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic combined chemotherapy protocols (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
breast neoplasms (5) 5
cancer therapies (5) 5
capecitabine (5) 5
combined modality therapy (5) 5
cyclophosphamide - administration & dosage (5) 5
dose-response relationship, drug (5) 5
double-blind (5) 5
epirubicin (5) 5
exemestane (5) 5
first-line therapy (5) 5
male (5) 5
neoadjuvant chemotherapy (5) 5
paclitaxel - therapeutic use (5) 5
tamoxifen - therapeutic use (5) 5
taxanes (5) 5
1st-line chemotherapy (4) 4
analysis (4) 4
androstadienes - adverse effects (4) 4
antineoplastic agents, hormonal - administration & dosage (4) 4
antineoplastic agents, hormonal - adverse effects (4) 4
antineoplastic agents, hormonal - pharmacology (4) 4
aromatase inhibitors - therapeutic use (4) 4
breast (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1700 - 1710
Summary Background Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CAPECITABINE | BIBW 2992 | EFFICACY | ONCOLOGY | MUTATIONS | ERBB FAMILY BLOCKER | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Vinblastine - therapeutic use | Brain Neoplasms - secondary | Breast Neoplasms - chemistry | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Brain Neoplasms - mortality | Antineoplastic Agents, Phytogenic - therapeutic use | Biomarkers, Tumor - antagonists & inhibitors | Republic of Korea | Antineoplastic Agents, Phytogenic - adverse effects | Brain Neoplasms - chemistry | Trastuzumab - therapeutic use | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease Progression | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Care and treatment | Breast cancer | Product development | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 28, pp. 19463 - 19468
BackgroundSince the approval of the first poly (adenosine diphosphate [ADP]) ribose polymerase inhibitor (PARPi; olaparib [Lynparza™]) for platinum-sensitive... 
OvCa | Molecular diagnostics | NGS | TBRCA1/2
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2003, Volume 21, Issue 6, pp. 968 - 975
Journal Article
2000, ISBN 9780864710727, 133
Book
Therapeutics and Clinical Risk Management, ISSN 1176-6336, 2008, Volume 4, Issue 1, pp. 189 - 204
Following promising data for metastatic breast cancer in terms of efficacy and safety profile, third-generation aromatase inhibitors (AI), anastrozole,... 
Adjuvant | Breast cancer | Aromatase inhibitors | Safety profile | breast cancer | aromatase inhibitors | adjuvant | safety profile | Review
Journal Article
by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
Journal Article
Blood, ISSN 0006-4971, 05/1999, Volume 93, Issue 10, pp. 3379 - 3390
Journal Article
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Index Medicus | Life Sciences
Journal Article